Navigation Links
Groundbreaking Study Gives Hope For Patients With Kidney Cancer

German researchers have developed what appears to be an effective vaccine against recurrent kidney cancers.// Kidney cancer accounts for about 3 percent of all cancers and causes about 12,000 deaths in the United States every year. The disease most often strikes those in their 50s and 60s. Standard treatment involves removal of all or part of the kidney. Unlike some other cancers, however, kidney cancer does not respond well to subsequent treatment with chemotherapy or radiotherapy. About half of all patients diagnosed with the disease will have a recurrence after the initial surgery.

Scientists tested vaccines custom made using the individual tumors from kidney cancer patients. The study involved 558 patients scheduled for surgery for kidney cancer. About half the group received six vaccine injections at four-week intervals following surgery. The other half received no additional treatment .The patients were then followed for five years. Among the 379 patients for whom follow up data were available, 77 percent of those who received the vaccinations were still alive without a recurrence of the disease. This compares to 68 percent of those who did not receive the injections.

Researchers conclude saying that,such a milestone could serve as a concrete step towards making adjuvant treatment of renal cancer a routine and effective intervention.
'"/>




Page: 1

Related medicine news :

1. Groundbreaking Asthma Intervention Lessons Help Inner-City Children
2. Tomato Sauce reduces Cancer Risk- Study
3. Study on obesity and heart failure
4. National Lung Study in the process
5. Study casts doubt on keyboard ills
6. Study reveals how stress can make you sick
7. Study reveals how stress can make you sick
8. Study supports vegetable diet
9. Study to look at early surgery to treat epilepsy
10. Its Never Too Late to Stop Smoking,Study Finds
11. New Technique to Study Infants Brain.
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology: